Data from the European registry for patients with McArdle disease (EUROMAC): functional status and social participation.
Glycogen storage disease V
Health care
International registry
McArdle disease
Rare diseases
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
25 07 2023
25 07 2023
Historique:
received:
22
03
2023
accepted:
10
07
2023
medline:
27
7
2023
pubmed:
25
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
The European registry for individuals with GSD5 and other muscle glycogenosis (EUROMAC) was launched to register rare muscle glycogenosis in Europe, to facilitate recruitment for research trials and to learn about the phenotypes and disseminate knowledge about the diseases. A network of twenty collaborating partners from eight European countries and the US contributed data on rare muscle glycogenosis in the EUROMAC registry. Following the initial report on demographics, neuromuscular features and comorbidity (2020), we here present the data on social participation, previous and current treatments (medication, supplements, diet and rehabilitation) and limitations. Furthermore, the following questionnaires were used: Fatigue severity scale (FSS), WHO Disability Assessment Scale (DAS 2.0), health related quality of life (SF36) and International Physical Activity Questionnaire (IPAQ). Of 282 participants with confirmed diagnoses of muscle glycogenosis, 269 had GSD5. Of them 196 (73%) completed all questionnaires; for the others, the data were incomplete. The majority, 180 (67%) were currently working. Previous medical treatments included pain medication (23%) and rehabilitation treatment (60%). The carbohydrate-rich diet was reported to be beneficial for 68%, the low sucrose diet for 76% and the ketogenic diet for 88%. Almost all participants (93%) reported difficulties climbing stairs. The median FSS score was 5.22, indicating severe fatigue. The data from the WHODAS and IPAQ was not of sufficient quality to be interpreted. The EUROMAC registry have provided insight into the functional and social status of participants with GSD5: most participants are socially active despite limitations in physical and daily life activities. Regular physical activity and different dietary approaches may alleviate fatigue and pain.
Sections du résumé
BACKGROUND
The European registry for individuals with GSD5 and other muscle glycogenosis (EUROMAC) was launched to register rare muscle glycogenosis in Europe, to facilitate recruitment for research trials and to learn about the phenotypes and disseminate knowledge about the diseases. A network of twenty collaborating partners from eight European countries and the US contributed data on rare muscle glycogenosis in the EUROMAC registry.
METHODS
Following the initial report on demographics, neuromuscular features and comorbidity (2020), we here present the data on social participation, previous and current treatments (medication, supplements, diet and rehabilitation) and limitations. Furthermore, the following questionnaires were used: Fatigue severity scale (FSS), WHO Disability Assessment Scale (DAS 2.0), health related quality of life (SF36) and International Physical Activity Questionnaire (IPAQ).
RESULTS
Of 282 participants with confirmed diagnoses of muscle glycogenosis, 269 had GSD5. Of them 196 (73%) completed all questionnaires; for the others, the data were incomplete. The majority, 180 (67%) were currently working. Previous medical treatments included pain medication (23%) and rehabilitation treatment (60%). The carbohydrate-rich diet was reported to be beneficial for 68%, the low sucrose diet for 76% and the ketogenic diet for 88%. Almost all participants (93%) reported difficulties climbing stairs. The median FSS score was 5.22, indicating severe fatigue. The data from the WHODAS and IPAQ was not of sufficient quality to be interpreted.
CONCLUSIONS
The EUROMAC registry have provided insight into the functional and social status of participants with GSD5: most participants are socially active despite limitations in physical and daily life activities. Regular physical activity and different dietary approaches may alleviate fatigue and pain.
Identifiants
pubmed: 37488619
doi: 10.1186/s13023-023-02825-z
pii: 10.1186/s13023-023-02825-z
pmc: PMC10367320
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Informations de copyright
© 2023. The Author(s).
Références
Curr Opin Endocrinol Diabetes Obes. 2021 Oct 1;28(5):441-445
pubmed: 34269712
Nat Clin Pract Neurol. 2008 Oct;4(10):568-77
pubmed: 18833216
Disabil Rehabil. 2022 Aug;44(16):4459-4466
pubmed: 33745407
Orphanet J Rare Dis. 2020 Nov 24;15(1):330
pubmed: 33234167
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
Disabil Rehabil. 2010;32(22):1870-6
pubmed: 20345240
Genet Med. 2015 Dec;17(12):1002-6
pubmed: 25741863
BMC Public Health. 2015 May 02;15:461
pubmed: 25934132
NCHS Data Brief. 2020 Jun;(369):1-8
pubmed: 32600518
Int J Behav Nutr Phys Act. 2011 Oct 21;8:115
pubmed: 22018588
J Inherit Metab Dis. 2020 Jul;43(4):778-786
pubmed: 32060930
Eur J Neurol. 2002 Nov;9(6):595-600
pubmed: 12453074
PLoS One. 2023 Mar 2;18(3):e0282536
pubmed: 36862646
Med Sci Sports Exerc. 2015 Apr;47(4):799-808
pubmed: 25058326
Neuromuscul Disord. 2021 Dec;31(12):1296-1310
pubmed: 34848128
Bull World Health Organ. 2010 Nov 1;88(11):815-23
pubmed: 21076562
Arch Neurol. 2008 Jun;65(6):786-9
pubmed: 18541798
Cochrane Database Syst Rev. 2014 Nov 12;(11):CD003458
pubmed: 25391139
BMC Med Res Methodol. 2008 Jul 15;8:47
pubmed: 18627632
Orphanet J Rare Dis. 2021 Oct 9;16(1):412
pubmed: 34627339
Front Physiol. 2021 Oct 15;12:744632
pubmed: 34721068
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD007931
pubmed: 22161416
N Engl J Med. 2003 Dec 25;349(26):2503-9
pubmed: 14695410
J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1359-63
pubmed: 19010947
Orphanet J Rare Dis. 2020 Oct 15;15(1):187
pubmed: 33054807